Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NEKTAR THERAPEUTICS Director's Dealing 2017

Apr 12, 2017

32134_dirs_2017-04-11_afb2e4b0-5936-4671-8e33-27ab61019dea.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2017-04-07

Reporting Person: Lingnau Lutz (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-04-07 Common Stock S 7000 $20.05 Disposed 23450 Direct

Footnotes

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan.

F2: This transaction was executed in multiple trades at prices ranging from $19.68 to $20.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.